158 related articles for article (PubMed ID: 38537670)
1. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
Paul SM; Yohn SE; Brannan SK; Neugebauer NM; Breier A
Biol Psychiatry; 2024 Mar; ():. PubMed ID: 38537670
[TBL] [Abstract][Full Text] [Related]
2. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Yohn SE; Weiden PJ; Felder CC; Stahl SM
Trends Pharmacol Sci; 2022 Dec; 43(12):1098-1112. PubMed ID: 36273943
[TBL] [Abstract][Full Text] [Related]
3. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC
Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639
[TBL] [Abstract][Full Text] [Related]
4. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
5. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
[TBL] [Abstract][Full Text] [Related]
6. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
Azargoonjahromi A
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38904739
[TBL] [Abstract][Full Text] [Related]
7. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.
Dean B
Expert Opin Investig Drugs; 2023; 32(12):1113-1121. PubMed ID: 37994870
[TBL] [Abstract][Full Text] [Related]
9. Positive allosteric modulation of M
Yohn SE; Conn PJ
Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
[TBL] [Abstract][Full Text] [Related]
10. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
Breier A; Brannan SK; Paul SM; Miller AC
Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
[TBL] [Abstract][Full Text] [Related]
11. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Development of Muscarinic Acetylcholine M
Takai K; Enomoto T
Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
JAMA Psychiatry; 2024 May; ():. PubMed ID: 38691387
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
15. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
16. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
17. M
Fu L; Luo Y; Niu L; Lin Y; Chen X; Zhang J; Tang W; Chen Y; Jiao Y
Bioorg Med Chem; 2024 May; 105():117728. PubMed ID: 38640587
[TBL] [Abstract][Full Text] [Related]
18. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of pharmacological properties of xanomeline and N-desmethylclozapine in rat brain membranes.
Odagaki Y; Kinoshita M; Ota T
J Psychopharmacol; 2016 Sep; 30(9):896-912. PubMed ID: 27464743
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
Dean B; Scarr E
Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
